REVIEW ON ARTICLEON POLYCYSTIC OVARY SYNDROME
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by hyperandrogenism and chronic anovulation. Depending on diagnostic criteria, 6% to 20% of reproductive-aged women are affected. Symptoms of PCOS arise during the early pubertal years. Both normal female pubertal development and PCOS are characterized by irregular menstrual cycles, anovulation, and acne. Owing to the complicated interwoven pathophysiology, discerning the inciting causes is challenging. PCOS typically involves hormonal imbalances, insulin resistance, and metabolic abnormalities, which significantly increase the risk of infertility, type 2 diabetes, and cardiovascular disease and affect the quality of life. The diagnosis of polycystic ovary syndrome requires at least two of the following criteria: oligoovulation and/or anovulation, clinical and/or biochemical evidence of hyperandrogenism and morphology of polycystic ovaries The aim of this article was to present a review of the literature by searching the databases Pubmed and Scielo, focusing on publications related to polycystic ovaries, including its pathogenesis, clinical manifestations, diagnosis, and therapeutic aspects.
Keywords:
Polycystic ovary syndrome, anovulation, cardiovascular disease, hyperandrogenism, oligoovulation
Downloads
Download data is not yet available.
References
1. AlEisa E, Gabr SA, Alghadir AH. Effects of supervised aerobic training on the levels ofantiMullerian hormone and adiposity measures inwomen with normo-ovulatory and polycystic ovary syndrome. J Pak Med Assoc 67, 499–507, 2017.
2. Stein IF, Leventhal ML. Amenorrhea associated withbilateral polycystic ovaries. Am J ObstetGynecol. 1935;29:181–191.
3. Moran LJ, Hutchison SK, Norman RJ, Teed HJLifestyle changes in women with polycystic ovary syndrome (review). Cochrane Database SystRev 2011, CD007506].
4. Sirmans SM,Pate K Epidemiology, diagnosis, andmanagement of polycystic ovary syndrome. ClinEpidemiol 2014;6:1–13.
5. Umland EM, Weinstein LC, Buchanan EM. Menstruation-related disorders. In: DiPiro JT, TalbertRL, Yee GC, et al., editors. Pharmacotherapy: APathophysiologic Approach. 8th ed. New York:McGraw-Hill; 2011. p. 1393.
6. National Institutes of Health. NIH Evidence-Based Methodology Work shop on Polycystic Ovary Syndrome:executivesummary, 2012.https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf. Accessed 23 February 2015.
7. Cinar N,Kizilarslanoglu MC, Harmanci A, et alDepression, anxiety and cardiometabolic risk inpolycystic ovarysyndrome. HumReprod2011;26:3339–3345.
8. Lin LH, Baracat MC, Gustavo AR, et al. Androgenreceptor gene polymorphism and polycystic ovary syndrome. Int J GynaecolObstet. 2013;120:115–118.
9. Himelein MJ,Thatcher SS Depression and body image among women with polycystic ovary syndrome. J Health Psychol 2006;11:616–625.
10. Dokras A Mood and anxiety disorders in womenwith PCOS. Steroids 2012;77:338–341 PubMedGoogleScholar
11. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ: The prevalence of polycysticovary syndrome in a community sample assessed undercontrasting diagnostic criteria. Hum Reprod. 2010, 25:544-551. 10.1093/humrep/dep399.
12. Azziz R, Marin C, Hoq L, Badamgarav E, Song P:Health care-related economic burden of the polycysticovary syndrome during the reproductive life span. JClin Endocrinol Metab. 2005, 90: 4650-4658. 10.1210/jc.2005-0628.
13. Vos T, Flaxman AD, et al. (2012). "Years lived withdisability (YLDs) for 1160 sequelae of 289 diseases andinjuries 1990-2010: a systematic analysis for the GlobalBurden of Disease Study 2010".
14. Lancet. 380 (9859):2163–96. Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA: Ovarian steroids modulateneuroendocrine dysfunction in polycystic ovary syndrome. J Endocrinol Invest. 2005, 28: 882-892.
15. Erhmann DA. Polycystic ovary syndrome. N Engl JMed. 2005; 352(12):1223-36.
16. da Silva BB, Lopes-Costa PV, Rosal MA,
dosSantos LG, Gontijo JA, Alencar AP, et al. Morphological and morphometric analysis of theadrenal cortex of androgenized female rats. GynecolObstet Invest. 2007; 64(1):44-8.
17. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications forpathogenesis. Endocr Rev. 1997; 18(6):774-800.
18. Dumitrescu R, Mehedintu C, Briceag I, PurcareaVL, Hudita D. The polycystic ovary syndrome: anupdate on metabolic and hormonal mechanisms. J MedLife. 2015; 8(2):142-5.
19. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, Fanta M, Vondra K, Skrha J:Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004, 89: 2942-2945.
20. Sóter MO, Ferreira CN, Sales MF, Candido AL, Reis FM, Milagres KS, et al. Peripheral blood-derivedcytokine gene polymorphisms and metabolic profile inwomen with polycystic ovary syndrome. Cytokine. 2015; 76(2):227-35.
21. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycysticovary syndrome during the reproductive life span. JClin Endocrinol 90, 4650–4658, 2005.
22. Targuer G, Zoppini G, Bonora E, Moghetti P. Hemostatic and fibrinolytic abnormalities in polycysticovary syn-Drome. Semin Thromb Hemost 40, 600–618, 2014.
23. Zuo T, Zhu M, Xu W. Roles of oxidative stress inPolycystic Ovary Syndrome and cancers. Oxid MedCell Longev 2016, 8589318, 2016.
24. BentleyLewis R, Seely E, Dunaif A. Ovarianhypertension: polycystic ovary syndrome. EndocrinolMetab Clin North Am. 2011; 40(2):433-49.
25. Ikeda K, Baba T, Morishita M, Honnma H, Endo T, Kiya T, et al. Longterm treatment withdehydroepiandrosterone may lead to follicular atresiathrough interaction with anti-Mullerian hormone. JOvarian Res. 2014; 7:46.
26. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril. 2005; 83(5):1343-6.
27. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatmentof polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(12):4565-92.
28. Tsikouras P, Spyros L, Manav B, Zervoudis S, Poiana C, Nikolaos T, et al. Features of polycysticovary syndrome in adolescence. J Sex Med. 2015;8(3):291-6.
29. Hsu M. Clinical characteristics in Taiwanese womenwith polycystic ovary syndrome. Clin Exp Reprod Med. 2015; 42(3):86-93.
30. Tosi F, Fiers T, Kaufman J, Dall’Alda M, Moretta R, Giagulli VA, et al. Implications of androgen assay accuracy in the phenotyping of women with polycysticovary syndrome. J Clin Endocrinol Metab. 2016;101(2):610-8.
31. EscobarMorreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and managem hirsutism: aconsensus statement by the Androgen Excess andPolycystic Ovary Syndrome Society. Hum ReprodUpdate. 2012; 18(2):146-70.
32. Lenart-Lipişska M, Matyjaszek-Matuszek B, Woşniakowska E, Solski J, Tarach JS, Paszkowski T. Polycystic ovary syndrome: clinical implication inperimenopause. Prz Menopauzalny. 2014; 13(6):348-51.
33. Rocha Gontijo JA, Gui DC, Boer PA, Dos SantosAR, Ferreira-Filho CP, Nery Aguiar AR, et al. Evaluation of arterial blood pressure and renal sodiumhandling in a model of female rats in persistent estrus. Clin Exp Hypertens. 2010; 32(6):385-9.
34. Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ (2012). "Emotional distress is a common riskin women with polycystic ovary syndrome: a systematicreview and meta-analysis of 28 studies". Hum. Reprod. Update. 18 (6): 638–51.
35. "Polycystic Ovarian Syndrome Treatment &Management". eMedicine. 25 October 2011. Archivedfrom the original on 16 November 2011. Retrieved 19 November 2011..,Krul-Poel YH, Snackey C, LouwersY, Lips P, Lambalk CB, Laven JS, Simsek S (2013). "The role of vitamin D in metabolic disturbances inpolycystic ovary syndrome: a systematic review". European Journal of Endocrinology (Review). 169 (6):853–65.
36. Unfer V, Carlomagno G, Dante G, Facchinetti F(2012). "Effects of myo-inositol in women with PCOS:a systematic review of randomized controlled trials". Gynecol. Endocrinol. 28 (7): 509–15. doi:10.3109/09513590.2011.650660. PMID22296306..,Zeng, Liuting; Yang, Kailin (2017-10-19). "Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis". Endocrine. 59 (1): 30-38.
37. Abbott DH, Zhou R, Bird IM, et al. Fetalprogramming of adrenal androgen excess: lessons froma nonhuman primate model of polycystic ovary syndrome. Endocrine Devices. 2008;13:145–15.
38. Abbott DH, Zhou R, Bird IM, et al. Fetalprogramming of adrenal androgen excess: lessons froma nonhuman primate model of polycystic ovary syndrome. Endocrine Devices. 2008;13:145–158.
2. Stein IF, Leventhal ML. Amenorrhea associated withbilateral polycystic ovaries. Am J ObstetGynecol. 1935;29:181–191.
3. Moran LJ, Hutchison SK, Norman RJ, Teed HJLifestyle changes in women with polycystic ovary syndrome (review). Cochrane Database SystRev 2011, CD007506].
4. Sirmans SM,Pate K Epidemiology, diagnosis, andmanagement of polycystic ovary syndrome. ClinEpidemiol 2014;6:1–13.
5. Umland EM, Weinstein LC, Buchanan EM. Menstruation-related disorders. In: DiPiro JT, TalbertRL, Yee GC, et al., editors. Pharmacotherapy: APathophysiologic Approach. 8th ed. New York:McGraw-Hill; 2011. p. 1393.
6. National Institutes of Health. NIH Evidence-Based Methodology Work shop on Polycystic Ovary Syndrome:executivesummary, 2012.https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf. Accessed 23 February 2015.
7. Cinar N,Kizilarslanoglu MC, Harmanci A, et alDepression, anxiety and cardiometabolic risk inpolycystic ovarysyndrome. HumReprod2011;26:3339–3345.
8. Lin LH, Baracat MC, Gustavo AR, et al. Androgenreceptor gene polymorphism and polycystic ovary syndrome. Int J GynaecolObstet. 2013;120:115–118.
9. Himelein MJ,Thatcher SS Depression and body image among women with polycystic ovary syndrome. J Health Psychol 2006;11:616–625.
10. Dokras A Mood and anxiety disorders in womenwith PCOS. Steroids 2012;77:338–341 PubMedGoogleScholar
11. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ: The prevalence of polycysticovary syndrome in a community sample assessed undercontrasting diagnostic criteria. Hum Reprod. 2010, 25:544-551. 10.1093/humrep/dep399.
12. Azziz R, Marin C, Hoq L, Badamgarav E, Song P:Health care-related economic burden of the polycysticovary syndrome during the reproductive life span. JClin Endocrinol Metab. 2005, 90: 4650-4658. 10.1210/jc.2005-0628.
13. Vos T, Flaxman AD, et al. (2012). "Years lived withdisability (YLDs) for 1160 sequelae of 289 diseases andinjuries 1990-2010: a systematic analysis for the GlobalBurden of Disease Study 2010".
14. Lancet. 380 (9859):2163–96. Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA: Ovarian steroids modulateneuroendocrine dysfunction in polycystic ovary syndrome. J Endocrinol Invest. 2005, 28: 882-892.
15. Erhmann DA. Polycystic ovary syndrome. N Engl JMed. 2005; 352(12):1223-36.
16. da Silva BB, Lopes-Costa PV, Rosal MA,
dosSantos LG, Gontijo JA, Alencar AP, et al. Morphological and morphometric analysis of theadrenal cortex of androgenized female rats. GynecolObstet Invest. 2007; 64(1):44-8.
17. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications forpathogenesis. Endocr Rev. 1997; 18(6):774-800.
18. Dumitrescu R, Mehedintu C, Briceag I, PurcareaVL, Hudita D. The polycystic ovary syndrome: anupdate on metabolic and hormonal mechanisms. J MedLife. 2015; 8(2):142-5.
19. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, Fanta M, Vondra K, Skrha J:Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004, 89: 2942-2945.
20. Sóter MO, Ferreira CN, Sales MF, Candido AL, Reis FM, Milagres KS, et al. Peripheral blood-derivedcytokine gene polymorphisms and metabolic profile inwomen with polycystic ovary syndrome. Cytokine. 2015; 76(2):227-35.
21. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycysticovary syndrome during the reproductive life span. JClin Endocrinol 90, 4650–4658, 2005.
22. Targuer G, Zoppini G, Bonora E, Moghetti P. Hemostatic and fibrinolytic abnormalities in polycysticovary syn-Drome. Semin Thromb Hemost 40, 600–618, 2014.
23. Zuo T, Zhu M, Xu W. Roles of oxidative stress inPolycystic Ovary Syndrome and cancers. Oxid MedCell Longev 2016, 8589318, 2016.
24. BentleyLewis R, Seely E, Dunaif A. Ovarianhypertension: polycystic ovary syndrome. EndocrinolMetab Clin North Am. 2011; 40(2):433-49.
25. Ikeda K, Baba T, Morishita M, Honnma H, Endo T, Kiya T, et al. Longterm treatment withdehydroepiandrosterone may lead to follicular atresiathrough interaction with anti-Mullerian hormone. JOvarian Res. 2014; 7:46.
26. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril. 2005; 83(5):1343-6.
27. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatmentof polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(12):4565-92.
28. Tsikouras P, Spyros L, Manav B, Zervoudis S, Poiana C, Nikolaos T, et al. Features of polycysticovary syndrome in adolescence. J Sex Med. 2015;8(3):291-6.
29. Hsu M. Clinical characteristics in Taiwanese womenwith polycystic ovary syndrome. Clin Exp Reprod Med. 2015; 42(3):86-93.
30. Tosi F, Fiers T, Kaufman J, Dall’Alda M, Moretta R, Giagulli VA, et al. Implications of androgen assay accuracy in the phenotyping of women with polycysticovary syndrome. J Clin Endocrinol Metab. 2016;101(2):610-8.
31. EscobarMorreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and managem hirsutism: aconsensus statement by the Androgen Excess andPolycystic Ovary Syndrome Society. Hum ReprodUpdate. 2012; 18(2):146-70.
32. Lenart-Lipişska M, Matyjaszek-Matuszek B, Woşniakowska E, Solski J, Tarach JS, Paszkowski T. Polycystic ovary syndrome: clinical implication inperimenopause. Prz Menopauzalny. 2014; 13(6):348-51.
33. Rocha Gontijo JA, Gui DC, Boer PA, Dos SantosAR, Ferreira-Filho CP, Nery Aguiar AR, et al. Evaluation of arterial blood pressure and renal sodiumhandling in a model of female rats in persistent estrus. Clin Exp Hypertens. 2010; 32(6):385-9.
34. Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ (2012). "Emotional distress is a common riskin women with polycystic ovary syndrome: a systematicreview and meta-analysis of 28 studies". Hum. Reprod. Update. 18 (6): 638–51.
35. "Polycystic Ovarian Syndrome Treatment &Management". eMedicine. 25 October 2011. Archivedfrom the original on 16 November 2011. Retrieved 19 November 2011..,Krul-Poel YH, Snackey C, LouwersY, Lips P, Lambalk CB, Laven JS, Simsek S (2013). "The role of vitamin D in metabolic disturbances inpolycystic ovary syndrome: a systematic review". European Journal of Endocrinology (Review). 169 (6):853–65.
36. Unfer V, Carlomagno G, Dante G, Facchinetti F(2012). "Effects of myo-inositol in women with PCOS:a systematic review of randomized controlled trials". Gynecol. Endocrinol. 28 (7): 509–15. doi:10.3109/09513590.2011.650660. PMID22296306..,Zeng, Liuting; Yang, Kailin (2017-10-19). "Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis". Endocrine. 59 (1): 30-38.
37. Abbott DH, Zhou R, Bird IM, et al. Fetalprogramming of adrenal androgen excess: lessons froma nonhuman primate model of polycystic ovary syndrome. Endocrine Devices. 2008;13:145–15.
38. Abbott DH, Zhou R, Bird IM, et al. Fetalprogramming of adrenal androgen excess: lessons froma nonhuman primate model of polycystic ovary syndrome. Endocrine Devices. 2008;13:145–158.
Published
30/06/2020
Statistics
182 Views | 152 Downloads
Citatons
How to Cite
[1]
C. CH.Ramyateja, M. Md.Salmasulthana, and J. N. J.Bhargava Narendhra, “REVIEW ON ARTICLEON POLYCYSTIC OVARY SYNDROME”, Int J Indig Herb Drug, pp. 15-20, Jun. 2020.
Section
Review Articles
Copyright © Author(s) retain the copyright of this article.
.